Zahra,
The 6 month fetal Hb percentage isn't good for a baseline, but it might give a hint at his ability to produce HbF by what its percentage was at that time. It doesn't matter how much HbF is currently present, but the level now gives a reference for future measurements. What you hope to see is even if the Hb level doesn't rise significantly, but remains somewhat stable, that the percentage of this Hb that is HbF will rise. When this happens, we know that the bad red blood cells are being suppressed while the red cells with higher amounts of fetal hemoglobin are becoming more prominent. This is far more important than it sounds because it means there is less bad hemoglobin produced, so fewer defective red cells and less "debris" in the bloodstream.
One thing to remember with hydroxyurea is the seeming paradox where bone marrow is suppressed to reduce the amount of defective beta globin produced, but the drug also can basically turn back on the gene that produced the gamma globin found in HbF. I really think this needs to be emphasized, as the benefits of hydroxyurea are more than a stabilization or rise in Hb. Reducing the amount of defective globins produced is one of the main goals of treatment for thalassemia. This is somewhat accomplished by keeping the Hb high through transfusions, and it is also accomplished by use of hydroxyurea. Both reduce bone marrow activity. Use of hydroxyurea in transfusing patients has worked in trials and some patients have become transfusion independent, while others have reduced their transfusion frequency. Every patient is unique, but the majority of patients in trails have found some benefit from hydroxyurea use. I also want to add that better drugs are in trials, which will make this approach to treatment much more productive.